cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8032991.v1
title: Additional file 1: of Elevated temperatures cause loss of seed set in common bean (Phaseolus vulgaris L.) potentially through the disruption of source-sink relationships

description: List of up- and down-regulated genes under heat stress condition in each of three genotypes of common bean. (XLSX 535 kb)
DOI: 10.6084/m9.figshare.8033000.v1
title: Additional file 2: of Elevated temperatures cause loss of seed set in common bean (Phaseolus vulgaris L.) potentially through the disruption of source-sink relationships

description: List of core genes that up- and down-regulated in all three genotypes. (XLSX 111 kb)
DOI: 10.6084/m9.figshare.8032910
title: MOESM2 of Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

description: Additional file 2: Table S1. Multiple comparisons of means anti-rPfCelTOS IgG, its subclasses, Th1/Th2 ratio and anti-rPfCelTOS avidity antibodies among the non-adjuvanted (group 1) and adjuvanted (groups 2—5) vaccine groups on day 38 of the first immunization using Tukey’s HSD post hoc test. Table S2. Multiple comparisons of mean IFN-γ, TNF, and IL-10 cytokines levels, IFN-γ/IL-10 and TNF/IL-10 ratios, and stimulation Index (SI) of MTT assay among all vaccine groups (1—5) with Tukey’s HSD post hoc test. Table S3. Effect of anti-rPfCelTOS IgG antibodies induced in mice on P. falciparum infectivity in An. stephensi.
DOI: 10.6084/m9.figshare.8032913
title: Additional file 6: of SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF

description: Table S4. RNA seq analysis of LoVo cells after SNHG15 depletion.(XLSX 163 kb)
DOI: 10.6084/m9.figshare.8032913.v1
title: Additional file 6: of SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF

description: Table S4. RNA seq analysis of LoVo cells after SNHG15 depletion.(XLSX 163 kb)
DOI: 10.6084/m9.figshare.8032910.v1
title: MOESM2 of Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

description: Additional file 2: Table S1. Multiple comparisons of means anti-rPfCelTOS IgG, its subclasses, Th1/Th2 ratio and anti-rPfCelTOS avidity antibodies among the non-adjuvanted (group 1) and adjuvanted (groups 2—5) vaccine groups on day 38 of the first immunization using Tukey’s HSD post hoc test. Table S2. Multiple comparisons of mean IFN-γ, TNF, and IL-10 cytokines levels, IFN-γ/IL-10 and TNF/IL-10 ratios, and stimulation Index (SI) of MTT assay among all vaccine groups (1—5) with Tukey’s HSD post hoc test. Table S3. Effect of anti-rPfCelTOS IgG antibodies induced in mice on P. falciparum infectivity in An. stephensi.
DOI: 10.6084/m9.figshare.8032901
title: MOESM1 of Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

description: Additional file 1: Figure S1. Western blot analysis of expressed PfCelTOS in E. coli. Figure S2. Indirect immunofluorescence antibody test (IFAT). Figure S3. Comparison of the anti-rPfCelTOS IgG, IgG1, IgG2a, IgG2b, and IgG3 antibodies in all vaccinated mice groups (1â 5) with the control mice groups (6â 10) on day 38 of the first immunization. Figure S4. Lymphocyte proliferation in cultured splenocyte cells of immunized mice (groups 1â 10) in the presence of rPfCelTOS in vitro.
DOI: 10.6084/m9.figshare.8032901.v1
title: MOESM1 of Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

description: Additional file 1: Figure S1. Western blot analysis of expressed PfCelTOS in E. coli. Figure S2. Indirect immunofluorescence antibody test (IFAT). Figure S3. Comparison of the anti-rPfCelTOS IgG, IgG1, IgG2a, IgG2b, and IgG3 antibodies in all vaccinated mice groups (1â 5) with the control mice groups (6â 10) on day 38 of the first immunization. Figure S4. Lymphocyte proliferation in cultured splenocyte cells of immunized mice (groups 1â 10) in the presence of rPfCelTOS in vitro.
DOI: 10.6084/m9.figshare.8032835
title: Additional file 2: of Effects of whole-body ELECTROMYOSTIMULATION on health and performance: a systematic review

description: Table S2. Results of the analyzed studies. (XLSX 27 kb)
DOI: 10.6084/m9.figshare.8032826
title: Additional file 1: of Effects of whole-body ELECTROMYOSTIMULATION on health and performance: a systematic review

description: Table S1. Characteristics of the studies included in the review. (XLSX 15 kb)
DOI: 10.6084/m9.figshare.8032835.v1
title: Additional file 2: of Effects of whole-body ELECTROMYOSTIMULATION on health and performance: a systematic review

description: Table S2. Results of the analyzed studies. (XLSX 27 kb)
DOI: 10.6084/m9.figshare.8032826.v1
title: Additional file 1: of Effects of whole-body ELECTROMYOSTIMULATION on health and performance: a systematic review

description: Table S1. Characteristics of the studies included in the review. (XLSX 15 kb)
DOI: 10.6084/m9.figshare.8032805
title: Additional file 3: of Population-level mathematical modeling of antimicrobial resistance: a systematic review

description: Table S4. Complete table of data extracted from each publication included in this review. (XLSX 203â kb)
DOI: 10.6084/m9.figshare.8032805.v1
title: Additional file 3: of Population-level mathematical modeling of antimicrobial resistance: a systematic review

description: Table S4. Complete table of data extracted from each publication included in this review. (XLSX 203â kb)
DOI: 10.6084/m9.figshare.8032754
title: MOESM9 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 9: Table S7. Combinations of uncorrelated markers and evaluation according to majority voting algorithm. For each combination, number of markers involved and AUC are shown.
DOI: 10.6084/m9.figshare.8032754.v1
title: MOESM9 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 9: Table S7. Combinations of uncorrelated markers and evaluation according to majority voting algorithm. For each combination, number of markers involved and AUC are shown.
DOI: 10.6084/m9.figshare.8032745
title: MOESM8 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 8: Table S6. Pearson correlation coefficients among each marker.
DOI: 10.6084/m9.figshare.8032739
title: MOESM6 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 6: Table S4. Performance of each marker in the single datasets.
DOI: 10.6084/m9.figshare.8032745.v1
title: MOESM8 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 8: Table S6. Pearson correlation coefficients among each marker.
DOI: 10.6084/m9.figshare.8032742
title: MOESM7 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 7: Table S5. Summary of the biomarker performance. The second column indicates the number of datasets on which the marker was tested; the last column is the difference between the maximum and the minimum AUC for each biomarker.
DOI: 10.6084/m9.figshare.8032739.v1
title: MOESM6 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 6: Table S4. Performance of each marker in the single datasets.
DOI: 10.6084/m9.figshare.8032742.v1
title: MOESM7 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 7: Table S5. Summary of the biomarker performance. The second column indicates the number of datasets on which the marker was tested; the last column is the difference between the maximum and the minimum AUC for each biomarker.
DOI: 10.6084/m9.figshare.8032727
title: MOESM4 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 4: Table S3. Per-patient summary of clinical classification where both DNA and RNA data are available.
DOI: 10.6084/m9.figshare.8032718
title: Additional file 6: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 3 XRD_C- Average data. (XLSX 94 kb)
DOI: 10.6084/m9.figshare.8032715
title: MOESM3 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 3: Table S2. Overview of responders and non-responders across datasets where both DNA and RNA data are available.
DOI: 10.6084/m9.figshare.8032718.v1
title: Additional file 6: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 3 XRD_C- Average data. (XLSX 94 kb)
DOI: 10.6084/m9.figshare.8032727.v1
title: MOESM4 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 4: Table S3. Per-patient summary of clinical classification where both DNA and RNA data are available.
DOI: 10.6084/m9.figshare.8032715.v1
title: MOESM3 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 3: Table S2. Overview of responders and non-responders across datasets where both DNA and RNA data are available.
DOI: 10.6084/m9.figshare.8032706
title: MOESM2 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 2: Table S1. Separation criteria for responder and non-responder groups in the datasets.
DOI: 10.6084/m9.figshare.8032703
title: Additional file 4: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 1 XRD_A. (XLSX 95 kb)
DOI: 10.6084/m9.figshare.8032706.v1
title: MOESM2 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 2: Table S1. Separation criteria for responder and non-responder groups in the datasets.
DOI: 10.6084/m9.figshare.8032709
title: Additional file 5: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 2 XRD_B. (XLSX 165 kb)
DOI: 10.6084/m9.figshare.8032703.v1
title: Additional file 4: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 1 XRD_A. (XLSX 95 kb)
DOI: 10.6084/m9.figshare.8032691
title: MOESM11 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 11: Table S9. GLM coefficient estimates, with their respective standard errors, t-values and p-values.
DOI: 10.6084/m9.figshare.8032709.v1
title: Additional file 5: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 2 XRD_B. (XLSX 165 kb)
DOI: 10.6084/m9.figshare.8032682
title: MOESM10 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 10: Table S8. Marker frequencies in the previous combinations with AUC greater than or equal to 0.65.
DOI: 10.6084/m9.figshare.8032691.v1
title: MOESM11 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 11: Table S9. GLM coefficient estimates, with their respective standard errors, t-values and p-values.
DOI: 10.6084/m9.figshare.8032682.v1
title: MOESM10 of Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

description: Additional file 10: Table S8. Marker frequencies in the previous combinations with AUC greater than or equal to 0.65.
DOI: 10.6084/m9.figshare.8032616
title: Additional file 12: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 3_RU-CO_07.09.2016. (TXT 376 kb)
DOI: 10.6084/m9.figshare.8032610
title: Additional file 11: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 2_Ru-Co_18.07.2016. (TXT 377 kb)
DOI: 10.6084/m9.figshare.8032616.v1
title: Additional file 12: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 3_RU-CO_07.09.2016. (TXT 376 kb)
DOI: 10.6084/m9.figshare.8032601
title: Additional file 10: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 1_Ru-Co_18.07.2016. (TXT 379 kb)
DOI: 10.6084/m9.figshare.8032610.v1
title: Additional file 11: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 2_Ru-Co_18.07.2016. (TXT 377 kb)
DOI: 10.6084/m9.figshare.8032601.v1
title: Additional file 10: of Liquid-phase hydrogenation of bio-refined succinic acid to 1,4-butanediol using bimetallic catalysts

description: 1_Ru-Co_18.07.2016. (TXT 379 kb)
DOI: 10.6084/m9.figshare.8032586
title: Additional file 1 of GatewayNet: a form of sequential rule mining

description: Supplementary Data. This file contains the transaction database for our synthetic data. (TXT 702 kb)
DOI: 10.6084/m9.figshare.8032589
title: Additional file 2 of GatewayNet: a form of sequential rule mining

description: Supplementary Data. This file contains the Markov chain used to generate sample.txns.txt (CSV 3 kb)
DOI: 10.6084/m9.figshare.8032586.v1
title: Additional file 1 of GatewayNet: a form of sequential rule mining

description: Supplementary Data. This file contains the transaction database for our synthetic data. (TXT 702 kb)
DOI: 10.6084/m9.figshare.8032589.v1
title: Additional file 2 of GatewayNet: a form of sequential rule mining

description: Supplementary Data. This file contains the Markov chain used to generate sample.txns.txt (CSV 3 kb)
DOI: 10.6084/m9.figshare.8032556
title: Additional file 2: of Pairing pedagogical and genomic advances to prepare advanced practice nurses for the era of precision health

description: Table S2. Shows the response options for assessment of satisfaction with the course. (XLSX 8 kb)
DOI: 10.6084/m9.figshare.8032556.v1
title: Additional file 2: of Pairing pedagogical and genomic advances to prepare advanced practice nurses for the era of precision health

description: Table S2. Shows the response options for assessment of satisfaction with the course. (XLSX 8 kb)
DOI: 10.6084/m9.figshare.8032550
title: Additional file 1: of Pairing pedagogical and genomic advances to prepare advanced practice nurses for the era of precision health

description: Table S1. Shows each competency, categorized by theme. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.8032550.v1
title: Additional file 1: of Pairing pedagogical and genomic advances to prepare advanced practice nurses for the era of precision health

description: Table S1. Shows each competency, categorized by theme. (XLSX 11 kb)
DOI: 10.6084/m9.figshare.8032496
title: Additional file 7: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: GO term enrichment. The number of total and differentially accumulated transcripts is shown for enriched GO terms. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.8032496.v1
title: Additional file 7: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: GO term enrichment. The number of total and differentially accumulated transcripts is shown for enriched GO terms. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.8032472
title: Additional file 3: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: Differentially accumulated transcripts from Atlantic salmon eggs and their annotation. (XLS 119 kb)
DOI: 10.6084/m9.figshare.8032463
title: Additional file 2: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: Blast results of transcripts from Atlantic salmon eggs. Transcript length, e-value, Refseq ID, GO-terms ID and GO-terms are given. The GO-term categories are cellular components (C), molecular function (F), and biological process (P). (XLS 19155 kb)
DOI: 10.6084/m9.figshare.8032472.v1
title: Additional file 3: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: Differentially accumulated transcripts from Atlantic salmon eggs and their annotation. (XLS 119 kb)
DOI: 10.6084/m9.figshare.8032463.v1
title: Additional file 2: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: Blast results of transcripts from Atlantic salmon eggs. Transcript length, e-value, Refseq ID, GO-terms ID and GO-terms are given. The GO-term categories are cellular components (C), molecular function (F), and biological process (P). (XLS 19155 kb)
DOI: 10.6084/m9.figshare.8032445
title: Additional file 11: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: miRNA sequence, count, and stastistic in Atlantic salmon egg from good versus poor egg quality groups (good and poor), over the course of postovulatory retention period (0, 14, 28â day post-ovulation). Each tab contain the statistical results obtained from EdgeR for each comparison. (XLS 489 kb)
DOI: 10.6084/m9.figshare.8032439
title: Additional file 9: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: KING-REX gene expression data. Normalized counts (Log2transformed) of KING-REX analysis in each sample, as calculated using the pipeline for gene expression analysis described in M&M. (TXT 375 kb)
DOI: 10.6084/m9.figshare.8032445.v1
title: Additional file 11: of Postovulatory maternal transcriptome in Atlantic salmon and its relation to developmental potential of embryos

description: miRNA sequence, count, and stastistic in Atlantic salmon egg from good versus poor egg quality groups (good and poor), over the course of postovulatory retention period (0, 14, 28â day post-ovulation). Each tab contain the statistical results obtained from EdgeR for each comparison. (XLS 489 kb)
DOI: 10.6084/m9.figshare.8032430
title: Additional file 7: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S5. Additional information in support to Table 1, right panel (KING-REX vs. CCLE transcriptome data). For each threshold and for each kinase in the KING-REX panel, the following information is reported: (i) the number of cell lines in which the kinase is considered present (P) or absent (N) in the reference dataset; (ii) the total number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN); (iii) the recall, precision and F-measure metrics used to obtain data in Table 1, right panel (KING-REX vs. CCLE transcriptome data). (XLSX 200 kb)
DOI: 10.6084/m9.figshare.8032436
title: Additional file 8: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S6. Additional information in support to Table 2. For each threshold and for each kinase in the KING-REX panel, the following information is reported: (i) the number of cell lines in which the kinase is considered present (P) or absent (N) in the reference dataset; (ii) the total number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN); (iii) the recall, precision and F-measure metrics used to obtain data in Table 2. (XLSX 204 kb)
DOI: 10.6084/m9.figshare.8032439.v1
title: Additional file 9: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: KING-REX gene expression data. Normalized counts (Log2transformed) of KING-REX analysis in each sample, as calculated using the pipeline for gene expression analysis described in M&M. (TXT 375 kb)
DOI: 10.6084/m9.figshare.8032430.v1
title: Additional file 7: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S5. Additional information in support to Table 1, right panel (KING-REX vs. CCLE transcriptome data). For each threshold and for each kinase in the KING-REX panel, the following information is reported: (i) the number of cell lines in which the kinase is considered present (P) or absent (N) in the reference dataset; (ii) the total number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN); (iii) the recall, precision and F-measure metrics used to obtain data in Table 1, right panel (KING-REX vs. CCLE transcriptome data). (XLSX 200 kb)
DOI: 10.6084/m9.figshare.8032436.v1
title: Additional file 8: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S6. Additional information in support to Table 2. For each threshold and for each kinase in the KING-REX panel, the following information is reported: (i) the number of cell lines in which the kinase is considered present (P) or absent (N) in the reference dataset; (ii) the total number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN); (iii) the recall, precision and F-measure metrics used to obtain data in Table 2. (XLSX 204 kb)
DOI: 10.6084/m9.figshare.8032418
title: Additional file 5: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S3. Sequence of primers used in RT-qPCR validation experiments. The sequence of the primers used for the detection of Assay_OUT and Assay_IN portions of ALK, RET, NTRK1, ROS1 and the reference control in RT-qPCR experiment are reported. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.8032424
title: Additional file 6: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S4. Additional information in support to Table 1, left panel (KING-REX vs. In-house transcriptome data). For each threshold and for each kinase in the KING-REX panel, the following information is reported: (i) the number of cell lines in which the kinase is considered present (P) or absent (N) in the reference dataset; (ii) the total number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN); (iii) the recall, precision and F-measure metrics used to obtain data in Table 1, left panel (KING-REX vs. In-house transcriptome data. (XLSX 204 kb)
DOI: 10.6084/m9.figshare.8032418.v1
title: Additional file 5: of Comprehensive kinome NGS targeted expression profiling by KING-REX

description: Table S3. Sequence of primers used in RT-qPCR validation experiments. The sequence of the primers used for the detection of Assay_OUT and Assay_IN portions of ALK, RET, NTRK1, ROS1 and the reference control in RT-qPCR experiment are reported. (XLSX 10 kb)